Semaglutide produces 18% weight loss after failed bariatric surgery

The wire

1. 01The double-blinded trial randomized 70 adults with under 20% weight loss after gastric bypass or sleeve gastrectomy to weekly semaglutide 2.4 mg or placebo, with a 63-patient intention-to-treat sample.
2. 02Adjusted treatment difference was -19.18% body weight, giving clinicians randomized evidence for a post-surgical population often managed by trial and error.
3. 03Eight serious adverse events and one suspected unexpected serious adverse reaction occurred; the trial was small and ran 68 weeks, leaving durability untested.

From the source

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

A suboptimal clinical response after metabolic and bariatric surgery (MBS) is common and carries considerable health concerns. Here a double-blinded, randomized (1:1), placebo-controlled trial using semaglutide 2.4 mg weekly (BARI-STEP) recruited adult participants at least 1 year after gastric bypass or sleeve gastrectomy with a suboptimal clinical response, defined as less than 20% weight loss f